Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor

US12134648B2 · kind B2 · utility

Assignee

• The Board of Regents of the University of Texas System · US

Inventors

• Michael A. Curran · Culver City, US
• Ashvin R. JAISWAL · Houston, US
• Dongxing Zha · Etna, US
• Carlo Toniatti · Houston, US
• Bianka Prinz · Lebanon, US
• Nadthakarn Boland · 安丰镇, CN
• Eric Krauland · Lebanon, US

Key dates

• Filing date: Mar 14, 2019
• Grant date: Nov 5, 2024
• Expiry date: Jun 15, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.